With the acquisition, Chicago-based Navigant said it plans to make Dymedex’s tools, methodologies and expertise available to its healthcare clients.
“In today’s medical device market, it is critical that companies create the conditions necessary to optimize growth, utilization, and adoption. Dymedex has a proven methodology to assist companies in accelerating the development of global markets. And while Dymedex has been successful in the medical technology field, we are excited by the opportunity to expand their methodologies into other life sciences areas such as pharmaceuticals and biotech,” Navigant global life sciences practice leader Eduardo Schur said in a press release.
Dymedex founders Joseph Galatowitsch and Ross Meisner, as well as the rest of the company’s employees, will join Navigant’s life sciences practice within its healthcare segment.
“Uncovering critical market insights and facilitating data-driven decisions is vital to the success of life science and med tech companies. The combination of Dymedex’s proprietary tools and methodologies with Navigant’s deep industry expertise and global footprint will enable our clients to fully capitalize on their opportunities,” Galatowitsch said in prepared remarks.